Noteworthy Tuesday Option Activity: TSLA, CVLT, AXSM

Options activity in CommVault Systems (CVLT) and Axsome Therapeutics (AXSM) showed heavy intraday flows: CVLT options traded 5,370 contracts (≈537,000 underlying shares), equal to ~92.7% of CVLT's one‑month average daily volume (579,565 shares), led by 1,031 contracts in the $90 call expiring Feb 20, 2026 (≈103,100 shares). AXSM saw 7,271 contracts (≈727,100 underlying shares), ~81.4% of its one‑month ADV (893,045 shares), driven by 5,527 contracts in the $280 call expiring Apr 17, 2026 (≈552,700 shares). Such concentrated call volumes indicate meaningful directional positioning that may amplify stock moves in those names but do not constitute market‑wide news.

Analysis

Market structure: Concentrated call volume in CVLT (Feb 20 $90) and AXSM (Apr 17 $280) implies directional bullish positioning or large hedged trades. If dealers are net short delta, we should expect immediate positive delta-hedging flows that can lift the underlying for days to weeks; the flows equal ~0.8–0.9x of each stock’s ADV which is large enough to move small-cap liquidity. Expect higher near-term IV and bid-ask widening in both names; sector peers (software for CVLT, biotech for AXSM) may see correlated volatility spillovers.

Risk assessment: Tail risks differ by ticker — AXSM carries binary clinical/FDA risk that can wipe option premia within days (high skew), while CVLT’s risk is operational/earnings-driven. Near-term (0–14 days) gamma-driven moves are most likely; medium-term (1–6 months) reversion to fundamentals; long-term (quarters) depends on earnings and trial readouts. Hidden risk: bulk option prints may be spreads or covered calls (low net delta) — open interest and block trade detail are critical; catalysts that could reverse trends include earnings, FDA filings, or large index/institutional trades.

Trade implications: For AXSM, the size of call flow signals aggressive bullish positioning — this favors a volatility-sensitive, directional trade sized conservatively (<=1–2% notional) or structured spreads to limit premium at risk. For CVLT, smaller absolute flow suggests tactical call exposure or put-sale spreads timed into upcoming earnings; market-makers’ short-delta posture creates an exploitable short-term momentum window. Cross-asset: minimal bond/FX impact, but buy-side risk-parity rebalances could force equity rotations if moves are large.

Contrarian angles: The consensus reading (buy calls = bullish) may be wrong if prints are dealer-structured or buy-writes — implied vol can stay elevated and stock may not rally. IV is likely overstated for AXSM around speculative prints; selling time decay via defined-risk credit spreads (after confirming net delta) can be profitable. Historical parallels: concentrated call blocks have produced transient squeezes (days–weeks) but often fade when not backed by fundamentals. Monitor OI and dealer delta to avoid being caught by hedged blocks.

Key Decisions for Investors

• AXSM directional: Establish a 1% portfolio long exposure via Apr 17, 2026 280/360 call debit spread (buy 280, sell 360) sized to risk 1% of portfolio; take profits at +50% premium, cut losses at -30% premium, rationale: capture gamma-driven upside while capping premium risk given binary clinical tail risk.
• CVLT tactical: Initiate a 0.75–1.0% long position by buying Feb 20, 2026 $90 call or 85/90 call debit spread (prefer spread if IV elevated); target 30–50% return, stop-loss -25% on option premium, rationale: exploit short-delta hedging into low-liquidity name for near-term momentum.
• Volatility sell: If 30-day IV for AXSM rises >20% vs its 90-day median and open interest increases >30% in 48 hours, sell 30–60 day defined-risk iron condors sized to 0.5% notional to capture mean-reversion in IV (close if underlying moves >10% intraday).